Estrella Immunopharma (ESLA) Receivables - Net (2023)
Estrella Immunopharma's (ESLA) quarterly Receivables - Net came in at $273066.0 in Q3 2023, little changed quarter-over-quarter from $273066.0 in Q2 2023.
Powered by 
Analysis
Estrella Immunopharma (ESLA) Receivables - Net (2023) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Receivables - Net for 1 consecutive years, with $273066.0 the latest figure, recorded in Q3 2023.
- On a quarterly basis, Receivables - Net changed N/A year-over-year to $273066.0 in Q3 2023; TTM through Sep 2023 was $273066.0, a N/A change from a year earlier, with the FY2023 full-year figure at $273066.0, changed N/A from the prior year.
- Receivables - Net was $273066.0 for Q3 2023 at Estrella Immunopharma, roughly flat from $273066.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $273066.0 in Q2 2023 and troughed at $273066.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Estrella Immunopharma | 28.22 Mn | 28.07 Mn | - |